Abstract
Background Tuberculosis (TB) cases and deaths in the United States fluctuated substantially during the COVID-19 pandemic. We analyzed multiple data sources to understand the factors contributing to these changes and estimated future TB trends.
Methods We identified four mechanisms potentially contributing to observed TB trends during 2020– 2023: immigration, respiratory contact rates, rates of accurate diagnosis and treatment initiation, and mortality rates for persons with TB disease. We employed a Bayesian approach to synthesize evidence on how these mechanisms changed during the pandemic and how they might have combined to produce observed 2020–2023 TB data, using a transmission-dynamic model to link mechanisms to TB outcomes. We also simulated a no-pandemic counterfactual scenario that assumed mechanisms followed pre-pandemic trends. We estimated TB outcomes associated with the pandemic until 2035 to capture lagged effects. We evaluated additional scenarios to estimate the individual effect of each mechanism.
Results Over the 2020–2035 study period, we estimate an additional 2,784 (95% uncertainty interval: 2,164–3,461) TB cases and 1,138 (1,076–1,201) TB deaths in the United States associated with changes occurring during the COVID-19 pandemic. The four mechanisms had offsetting effects – decreases in TB diagnosis rates and increases in TB mortality rates led to more TB deaths, while reductions in contact rates reduced TB deaths. Immigration changes initially reduced TB deaths, but increased deaths over time.
Discussion While the direct impacts of the COVID-19 pandemic occurred between 2020–2023, these changes may continue to influence TB incidence and mortality in future years.
Summary The COVID-19 pandemic disrupted steady declines in U.S. tuberculosis rates. Despite sharp decreases in TB cases over 2020–2021, we projected there would be 2,784 additional TB cases and 1,138 additional TB deaths during 2020–2035 associated with pandemic-related changes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the CDC, National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA; #5NU38PS004644) (N.A.S., N.A.M., T.C., J.A.S.), and the National Institutes of Health (R01AI146555-02) (C.R.H.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Harvard University determined this research to constitute non human subjects research (IRB22-1328).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Apart from National TB Surveillance System data, all data used in this analysis represent deidentified publicly available datasets. National TB Surveillance System data contain information abstracted from the national tuberculosis case report form called the Report of Verified Case of Tuberculosis (RVCT) (OMB No. 0920-0728). These data have been reported voluntarily to CDC by state and local health departments and are protected under the Assurance of Confidentiality (Sections 306 and 308(d) of the Public Health Service Act, 42 U.S.C. 242k and 242m(d)), which prevents disclosure of any information that could be used to directly or indirectly identify patients. For more information, see the CDC/ATSDR Policy on Releasing and Sharing Data (at https://stacks.cdc.gov/view/cdc/7563). A limited dataset is available at http://wonder.cdc.gov/tb.html. Researchers seeking additional National TB Surveillance System data may request access through the National Center for Health Statistics Research Data Centers (https://www.cdc.gov/rdc/b1datatype/tuberculosis.htm).
